Petvivo Holdings to File Quarterly Report on November 13, 2026; Welcomes Shareholder Questions and Dialogue

PetVivo shifts to SEC filings only for quarterly results, ending separate earnings releases.

What the company is saying

PetVivo Holdings, Inc. (OTCQB:PETV) will file its Quarterly Report on Form 10-Q for the fiscal second quarter ended September 30, 2026, on November 13, 2026. Starting with this filing, the company will no longer issue separate quarterly press releases or hold earnings conference calls, instead relying solely on SEC filings for financial disclosures. The company frames this as a procedural change, emphasizing continued transparency through required SEC reports and encouraging shareholders to access filings via EDGAR. Management states that this approach may be revisited if the company uplists to a national securities exchange, at which point traditional earnings releases and calls could resume, subject to listing approvals. The announcement highlights PetVivo’s focus on innovative medical devices for animals and humans, a portfolio of twelve issued and pending patents, and six trade secrets. The lead product, SPRYNG with OsteoCushion technology, is described as commercially available for treating joint issues in cats, dogs, and horses. CEO John Lai is named as the company contact, and management invites direct shareholder engagement following report reviews.

What the data suggests

The only dated operational fact is the planned 10-Q filing for the quarter ended September 30, 2026, scheduled for November 13, 2026. No revenue, profit, cash, or growth figures are disclosed in this announcement. The company quantifies its intellectual property as twelve issued and pending patents and six trade secrets, but does not provide pipeline details, financial metrics, or product sales data. SPRYNG with OsteoCushion technology is confirmed as commercially available, but no adoption or revenue figures are given. The data quality for financial analysis is low, as the release is strictly procedural about disclosure practices rather than business performance. All forward-looking statements regarding uplisting or resuming broader communications are explicitly conditional and not presented as imminent.

Analysis

The announcement is a procedural update regarding how PetVivo Holdings, Inc. will communicate its quarterly financial results, shifting from press releases and conference calls to SEC filings only. The tone is factual and does not exaggerate operational or financial progress. While there are some forward-looking statements about potentially resuming broader communications if the company uplists to a national exchange, these are clearly conditional and not presented as imminent or guaranteed. No claims are made about financial performance, growth, or product breakthroughs, and there is no mention of capital outlays or timelines for benefit realization. The only operational facts disclosed are the upcoming 10-Q filing date, the company's intellectual property portfolio, and the commercial availability of its lead product. There is no evidence of narrative inflation or overstatement.

Risk flags

• ●The move to SEC filings as the sole channel for quarterly financial results reduces the immediacy and accessibility of information for some investors, potentially lowering engagement or delaying market reactions.
• ●No financial or operational performance data is disclosed in this announcement, which limits investor ability to assess current business health or trajectory until the 10-Q is filed.
• ●The company’s stated intention to revisit its communication approach is tied to a possible future uplisting, which is not guaranteed and is subject to regulatory approvals and listing requirements, introducing uncertainty about when or if traditional earnings communications will resume.

Bottom line

PetVivo Holdings, Inc. is ending separate quarterly earnings releases and conference calls, shifting all financial disclosures to SEC filings starting with its November 13, 2026, 10-Q for the quarter ended September 30, 2026. This procedural change means investors must rely on EDGAR for timely financial updates, with no additional commentary or Q&A from management until further notice. No financial or operational metrics are provided in this announcement, so investors will have to wait for the 10-Q to assess business performance. The company’s willingness to resume broader communications is explicitly tied to a potential future uplisting, which remains speculative and subject to approvals. The most actionable takeaway is that investors should monitor SEC filings directly for all future financial information from PetVivo.

Announcement summary

(OTCQB:PETV) PetVivo Holdings, Inc. announced that it plans to file its Quarterly Report on Form 10-Q for the fiscal second quarter ended September 30, 2026, on Friday, November 13, 2026. Beginning with this filing and continuing in subsequent quarters, the company intends to communicate its quarterly financial results and related disclosures solely through its SEC filings. PetVivo does not intend to issue separate quarterly results press releases or conduct quarterly earnings conference calls going forward. As a company traded on the OTCQB Venture Market, PetVivo will continue to provide public access to its financial results and related disclosures through its required SEC reports. Shareholders are encouraged to review these reports through the SEC’s EDGAR database. The company intends to revisit this approach as its business and investor base evolve and currently anticipates resuming quarterly earnings releases and conference calls in connection with any future uplisting to a national securities exchange. Any such uplisting would be subject to applicable listing requirements and approvals. This change in communication format does not change PetVivo’s commitment to keeping shareholders informed and maintaining an open dialogue. The company welcomes questions, feedback, and requests for discussion following review of its reports. Management remains available to discuss PetVivo’s publicly disclosed results, business activities, and strategic priorities. PetVivo Holdings, Inc., together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc., and PetVivo AI, Inc., is a biomedical device company focused on the development, manufacturing, commercialization, and licensing of innovative medical devices, biomaterials, and therapeutics for animal and human health. The company’s strategy is to leverage its proprietary technologies, intellectual property, and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the company’s biomaterials, products, production processes, and methods of use. The company’s lead product, SPRYNG with OsteoCushion technology, is a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs, and horses, and is currently available for commercial sale. John Lai is the CEO of PetVivo Holdings, Inc.

Disagree with this article?